Get the Stockscreener App
1.5838
1.53%
-0.0462
Palisade Bio Inc stock is traded at $1.5838, with a volume of 360.83K.
It is down -1.53% in the last 24 hours and down -15.08% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.63
Open:
$1.66
24h Volume:
360.83K
Relative Volume:
0.07
Market Cap:
$237.98M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1132
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-7.23%
1M Performance:
-15.08%
6M Performance:
+122.95%
1Y Performance:
+63.78%
1-Day Range:
$1.59
$1.6697
1-Week Range:
$1.60
$1.77
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.595 | 243.20M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.58 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.26 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.82 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.86 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
355.69 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com Canada
Palisade Bio CEO Finley sells $6818 in shares - Investing.com Nigeria
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire
Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - markets.businessinsider.com
Palisade Bio appoints two IBD experts to clinical advisory board - Investing.com
Two IBD leaders join Palisade Bio push on PALI-2108 for colitis and Crohn's - stocktitan.net
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat
Published on: 2026-01-19 10:30:24 - baoquankhu1.vn
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com Nigeria
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com India
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
0.66%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):